MedTrace Logo

Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL)

NCT01419691 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2016-01-18

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and effectiveness of auranofin to treat patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or prolymphocytic lymphoma (PLL).

Conditions

Interventions

DRUG

auranofin

6 mg twice a day for a total of 12 mg total daily dose

Sponsors & Collaborators

  • The Leukemia and Lymphoma Society

    collaborator OTHER

  • Kansas Bioscience Authority

    collaborator UNKNOWN

  • Therapeutics for Rare and Neglected Diseases (TRND)

    collaborator NIH

  • University of Kansas Medical Center

    lead OTHER

Principal Investigators

  • Suman Kambhampati, MD · University of Kansas Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2015-09-30
Completion
2015-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01419691 on ClinicalTrials.gov